Month: February 2022

NEWPORT NEWS, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) — Global engineering and defense technologies provider HII (NYSE:HII) announced today the promotion of Edmond Hughes to executive vice president and chief human resources officer. Hughes, formerly the vice president of human resources and administration contracts at HII’s Ingalls Shipbuilding division and at Northrop Grumman Shipbuilding since 2006, will replace William “Bill” R. Ermatinger, who will retire on April 1 after 35 years of service. HII also appointed Susan Jacobs to replace Hughes as the vice president, human resources and administration of Ingalls Shipbuilding, effective April 1. “Bill’s leadership has been critical to the evolution and growth of HII. It is a testament to his success that we have a deep bench of talent to fill his shoes,” said Mike Petters, president...

Press Release Atos and Nokia join forces to enhance businesses’ digital applications with full private 4/5G networks services Paris, France – February, 24, 2022 – Atos and Nokia today announce a global partnership to provide businesses with market leading 4/5G private wireless networking solutions along with associated digital services and to work together to develop further innovative services. This partnership will help enterprises reach enhanced operational efficiency while enabling new ways of working. Hosted either on Atos or Nokia servers, the joint offering brings together the two leaders in cloud & edge computing capabilities to accompany businesses in their digitalization journey towards 4.0 industry. The collaboration leverages Nokia Digital Automation Cloud (DAC), an industrial-grade private wireless connectivity &...

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, March 3rd, 2022. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company’s website at www.siga.com under the ‘Events & Presentations’ tab in the Investor Relations section, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-877-425-9470 for domestic callers or 1-201-389-0878 for international callers. A replay of the call will be...

New Canopies Designed By Morali Architects & Amergy Solar Inc. NEW YORK, NY, Feb. 24, 2022 (GLOBE NEWSWIRE) — Green Stream Holdings Inc. (OTC PINK: GSFI) (“the Company”) (https://greensolarutility.com) an emerging leader in the solar utility and finance space, announced that its All Faiths Cemetery Solar Facility Project has been approved by The New York City (NYC) Department of Buildings for compliance with all applicable zoning and construction regulations. The multi-million-dollar deal is being financed by Green Stream Holdings, Inc. to cover equipment and installation costs. CEO James DiPrima said: “The All Faiths Cemetery Project has cleared first phase towards completion of a 3.3 Mega Watt Solar Facility in All Faiths Cemetery, Middle Village Queens NY. We are evaluating 2 back of house areas: Area1. The...

Figure 1. Locations of all 2021 Phase 1 diamond drill holes completed on the Santo Domingo Silver Property, the main mineralized vein systems (red dashes), and historical drill holes (black).TORONTO, Feb. 24, 2022 (GLOBE NEWSWIRE) — Stroud Resources Ltd. (TSXV:SDR) (“Stroud” or the “Company”) is pleased to announce that it has begun its Phase 2 diamond drilling program on its Santo Domingo Silver Property (“Santo Domingo” or the “Property”), located in Hostotipaquillo Region of Jalisco, Mexico. A 3,500 m program is planned for this phase of drilling, targeting the newly discovered Zopilote Vein (previously “New Vein”), the Guadalupe Vein and the La Raya Vein on which there is a current National Instrument 43-101 mineral resource estimate (see Stroud news releases dated 20 November 2017). In its 2021 Phase 1 diamond drilling...

ROUYN-NORANDA, Québec, Feb. 24, 2022 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to inform shareholders that three of the largest data analytical firms have positively evaluated Globex. The firms listed have published the indicated comments reported below on the dates marked summarizing in part extensive analysis now available from many brokerage firms which pay for such analysis.Data Analyst Firm Report Date Principal CommentsMorningstar Inc. February 23, 2022 $2.69 (Fair Value Estimate) “Globex is valued at a 51% discount.”CFRA February 18, 2022 Strong Buy, “Globex’s overall score...

Preliminary safety data has shown that PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and well tolerated without evidence of enhanced or significant toxicity FLORHAM PARK, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) —  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology, today announced the presentation of preliminary safety data. The data are based on a total of 18 checkpoint inhibitor (CPI) naïve patients from the Company’s ongoing VERSATILE-002 Phase 2 study. The study is being conducted in collaboration with Merck (known...

RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) — North Carolina-headquartered First Citizens Bank continues to be recognized as a leader in small business and middle market banking, receiving a total of 22 Greenwich Excellence and Brand Awards for 2021. “These awards place First Citizens among the top tier of business banks in the nation and are a testament to the quality and depth of services we provide our customers,” said Patrick Noble, business services executive for First Citizens Bank. “For 124 years we’ve worked alongside our business clients, building strong, mutual relationships and helping them grow and manage their money. These honors signify the great confidence they place in us, and we’re extremely proud to be recognized by those we serve.” First Citizens garnered 22 awards —17 wins in the Small Business Banking category...

Shareholders can now exchange blocks of 20 shares of common stock into a tradable $25 perpetual, convertible preferred stock with a 6% annual dividend Offering price represents a 127% premium to the closing share price of $0.55 on January 25, 2022, the day prior to the commencement of the original Offer Shares tendered will be retired, reducing share count by approximately 30% Participating shareholders should instruct their broker to tender their shares well before the expiration time of 11:59 p.m. EST on March 10, 2022, to give their broker enough time to tender their sharesIRVING, Texas, Feb. 24, 2022 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela” or the “Company”) (NASDAQ: XELA) announced today that it has amended the previously announced offer (the “Offer”) to exchange up to 100,000,000 shares of its Common Stock...

Media Release COPENHAGEN, Denmark, and BOTHELL, Wash., February 24, 2022Data from the innovaTV 207 global phase 2 trial to be presented at the American Society for Radiation Oncology (ASTRO) 2022 Multidisciplinary Head and Neck Cancers SymposiumGenmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (TIVDAK®) as a monotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN) who experienced disease progression on or after a first-line platinum-containing regimen and a checkpoint inhibitor. Early results showed tisotumab vedotin demonstrated a manageable safety profile and promising preliminary antitumor activity in this patient population with the primary endpoint of confirmed objective response...